

## Scancell

FY25: Full steam ahead with iSCIB1+

11 September 2025

- Following recent updates from the Phase II [SCOPE](#) study, notably the strength of the PFS data and selection of iSCIB1+ for future development, the focus remains on accelerating plans to start a registrational global late-stage trial in advanced melanoma in 2026. Importantly, discussions have now been scheduled with regulators in the US, UK and Europe, a key step to gain the necessary approvals to initiate the trial; a pre-IND meeting with the FDA is planned for this year. In parallel, active discussions are also ongoing with potential partners to optimise the development path.
- The SCOPE data ([August 2025 Update](#)) showed that SCIB1/iSCIB1+ can offer improved PFS (progression-free survival) and other benefits when added to standard-of-care CPIs (checkpoint inhibitors) in first-line treatment of advanced melanoma. iSCIB1+ was selected as the optimal candidate for further development as it addresses a broader population (c 80% of patients), double that of SCIB1, and has a longer patent life. Further SCOPE data are expected during Q425, including Cohort 3 iSCIB1+ patients that have not yet had scans, longer-term PFS data (and eventually initial OS data), plus first data from Cohort 4, which should help to refine current study plans.
- Data from the Phase I/II [ModiFY](#) study of Modi-1 are also expected this year. These include: (1) interim data from the renal cell carcinoma (RCC) cohort, which should establish whether a Modi-1/doublet CPI combination can bring potential improvements in this first-line setting; and (2) further data from the H&N cohort (coupled with pembrolizumab) which could help underpin investigator interest in exploring Modi-1 in the H&N neoadjuvant setting.
- FY25 revenues (for the year to 30 April 2025) were £4.7m (FY24: nil) from the \$6m Genmab upfront for the second GlyMab deal (\$1m received in June 2024 and \$5m in December 2024). R&D expenses increased to £14.7m (FY24: £12.9m) which included continued spend on SCOPE and ModiFY, in addition to iSCIB1+ manufacturing scale up in readiness for future trials. G&A was well controlled, decreasing to £4.8m (FY23: £5.4m). Operating loss was narrower at £15.0m (FY24: £18.3m) owing to the Genmab milestone, whilst the net loss was wider at £12.3m (FY24: £5.9m), as FY24 included £9.9m non-cash income relating to the convertible loan note. Cash at end April was £16.9m (FY24: £14.8m), which provides a runway through to calendar Q326.

**Trinity Delta view:** Scancell continues to advance plans to progress its highly promising ImmunoBody “off-the-shelf” DNA cancer vaccine. Selected candidate iSCIB1+ could offer meaningful benefits to a large, identifiable group of advanced melanoma patients. Critical path meetings with regulators are scheduled, and discussions are also ongoing with potential partners, in order to expeditiously initiate a potentially registrational trial in 2026. Further iSCIB1+ data are expected this year, in addition to data from second clinical candidate Modi-1, with upside potential from both. Scancell has the cash to deliver on these plans, with a runway to calendar Q326; this could be extended by potential business development transaction(s), which are being explored across the pipeline. Our Scancell rNPV based valuation is £373m, or 36p/share.

Price	8.54p
Market Cap	£88.6m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP
Corporate client	Yes

### Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

### Analysts

**Lala Gregorek**  
lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

**Philippa Gardner**  
pgardner@trinitydelta.org  
+44 (0) 20 3637 5042

**Philippa Gardner**

[pgardner@trinitydelta.org](mailto:pgardner@trinitydelta.org)

+44 (0) 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 (0) 20 3637 5043

**Franco Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2025 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)